PDCD1 and neoplasm: Recent study suggests that renal cell carcinomas (RCC) patients are more likely to experience immune-related anemia from PD-1 inhibitors, because existing tumor burden in the kidney may impair the capability for renal elimination of metabolites from the blood, leading to the accumulation of toxic metabolites (Sui et al., 2018).